Search

Displaying results 4051 - 4060 of 10000 in total
  1. Drug

    Cynodon dactylon pollen

    go.drugbank.com/drugs/DB10351
    Approved

    It can be cutaneously, intradermally and subcutaneously administered to initiate an immune response in case of an allergic reaction.

  2. Drug

    Triacetin

    go.drugbank.com/drugs/DB16005
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    AN-9

    go.drugbank.com/drugs/DB05103
    Investigational

    Pivaloyloxymethyl butyrate (AN-9), an acyloxyalkyl ester prodrug of butyric acid (BA), exhibited low toxicity and significant anticancer activity in vitro and in vivo. … greater potency than BA at inducing malignant cell differentiation and tumor growth inhibition and has demonstrated more favorable toxicological, pharmacological, and pharmaceutical properties than BA in

    Synonyms: AN-9
  4. Drug

    QS-21

    go.drugbank.com/drugs/DB05400
    Investigational

    As a vaccine additive, it is currently being evaluated in clinical trials in a variety of disease areas by Antigenics. … QS-21 is an investigational adjuvant, which is a substance added to vaccines and other immunotherapies that is designed to enhance the body’s immune response to the antigen contained within the treatment

  5. Drug

    Aluminum zirconium pentachlorohydrex gly

    go.drugbank.com/drugs/DB11277
    ApprovedWithdrawn

    Aluminum zirconium pentachlorohydrex gly, or Aluminum Zirconium Tetrachlorohydrex Glycine, is commonly used as an antiperspirant in many deodorant products.

  6. Drug

    PF-03187207

    go.drugbank.com/drugs/DB05746
    Investigational

    Based on the very promising preclinical results and on the well-known activities of nitric oxide, PF-03187207 is expected to have an increased capacity to reduce high IOP. … The development of abnormally high IOP, due to blockage or malfunction of systems controlling the amount of fluid in the eye, is believed to be one of the principal causes of glaucoma.

  7. Drug

    Ambenonium

    go.drugbank.com/drugs/DB01122
    ApprovedWithdrawn

    It is used in the management of myasthenia gravis.

  8. Drug

    Dodecyldimethylamine N-oxide

    go.drugbank.com/drugs/DB04147
    Experimental

    Categories: Compounds used in a research, industrial, or household settingSynonyms: N,N-Dimethyldodecylamine oxide, Dimethyldodecylamine N-oxide
  9. Drug

    CHF 4227

    go.drugbank.com/drugs/DB05882
    Experimental

    The compound has a high receptor affinity and has shown promising efficacy in the prevention of bone loss in animal models of osteoporosis. … Additionally, the compound has shown no uterotrophic activity suggesting a potential therapeutic advantage over drugs normally used in postmenopausal therapy.

  10. Drug

    Vimseltinib

    go.drugbank.com/drugs/DB17520
    ApprovedInvestigational

    A265035] It is intended to provide a safer alternative to [pexidartinib], a previously approved CSF1R inhibitor associated with significant liver toxicity - the greater selectivity of vimseltinib results in … [L52230,A265035] Vimseltinib - under the brand name Romvimza - was approved by the FDA in February 2025 for the treatment of tenosynovial giant cell tumours for which surgical resection is not appropriate